What does it actually take to get a major partnership over the finish line? At BioStock Life Science Summit 2026, the leadership behind Hansa Biopharma, AlzeCure Pharma and SAGA Diagnostics, three Swedish companies that have all recently struck deals in the billion-kronor range, shared their experiences of dealmaking from the Nordics.
In a discussion moderated by Anna Gran, Managing Director of Askel and an experienced dealmaker with a background in big pharma business development, venture capital and alliance management, the panellists looked behind their recent licensing and commercial agreements. The conversation covered what it took to land the deals, how long the processes were and which strategic considerations led to the outcome, as well as the practical reality of finding the right partners, handling gruelling due diligence and negotiating terms you can live with.
On stage were Renée Aguiar-Lucander, CEO of Hansa Biopharma, Johan Sandin, interim CEO of AlzeCure, and Lao Saal, founder of SAGA Diagnostics and Medical Director of DoMore Diagnostics, all of whom played a central role in making their companies’ deals happen.
See the full panel discussion “Closing the Deal – Nordic Success Stories” below.
